Evidence Table E61. Binge eating disorder drug treatment – part 7

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Arnold, 200266 | CGI-S  HAM-D | CGI-S, mean (SD):  G1: 4.2 (0.4)  G2: 4.3 (0.6)  (P = NS)  HAM-D, mean (SD):  G1: 4.8 (4.3)  G2: 4.2 (2.9)  (P = NS) | CGI-S, mean (SD):  G1: 2.2 (1.4)  G2: 3.3 (1.4)  Diff between groups (P = NR)  Diff between groups in change over time (time trend analysis, P = 0.032; endpoint analysis, P = 0.012), G1 better than G2  HAM-D, mean (SD):  G1: 2.6 (3.0)  G2: 5.5 (4.1)  Diff between groups (P = NR)  Diff between groups in change over time (time trend analysis, P = NS; endpoint analysis, P = 0.003), G1better than G2 |
| Brownley, 201367 | Quick Inventory of Depressive Symptomatology; QIDS-SR | QIDS-SR  baseline  G1: 7.1 (5.4)  G2: 8.1 (3.0)  G3: 5.7 (3.0)  p = 0.99 | QIDS-SR  Monthly rate of change  G1:-0.30 (0.21)  G2: -0.41 (0.19)  G3: -0.03 (0.21)  p = ns |
| Guerdjikova, 200968 | CGI-S  YBOCS-BE  YBOCS BE Obsessions  YBOCS BE Compulsions  MADRS  BIS Total  BIS Attention  BIS Motor  BIS Nonplanning | CGI-S (M,SD)  G1: 4.46 (0.65)  G2: 4.52 (0.59)  YBOCS BE(M,SD)  G1: 19.42 (4.12)  G2: 20.68 (4.72)  YBOCS BE Obsessions (M,SD)  G1: 9.04 (2.62)  G2: 9.84 (2.98)  YBOCS-BE Compulsison (M,SD)  G1: 10.38 (2.30)  G2: 10.84 (2.01)  MADRS (M,SD)  G1: 3.85 (3.83)  G2: 3.04 (3.35) | CGI-S (M,SD):  G1: 2.38 (1.44)  G2: 2.20 (1.32)  Diff between groups (P = 0.519)  Diff between groups in change over time (P =0.759)  YBOCS BE(M,SD)  G1: 8.68 (7.91)  G2: 7.08 (6.55)  Diff between groups (p=0.102)  Diff between groups in change over time (p=0.109)  YBOCS BE Obsessions (M,SD)  G1: 4.52 (4.11)  G2: 3.80 (3.30)  Diff between groups (p=0.111) |

Evidence Table E61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 200968  (continued) |  | BIS Total (M,SD)  G1: 66.23 (10.56)  G2: 35.88 (9.62)  BIS Attention (M,SD)  G1: 17.88 (3.71)  G2: 11.50 (3.87)  BIS Motor (M,SD)  G1: 22.19 (3.96)  G2: 12.60 (3.51)  BIS Nonplanning (M,SD)  G1: 26.15 (5.24)  G2: 12.24 (4.16) | Diff between groups in change over time (p=0.188)  YBOCS-BE Compulsison (M,SD)  G1: 4.16 (4.00)  G2: 3.28 (3.40)  Diff between groups (p=0.144)  Diff between groups in change over time (p=0.079)  MADRS (M,SD)  G1: 2.16 (3.34)  G2: 0.56 (1.23)  Diff between groups (p=0.472)  Diff between groups in change over time (p=0.944)  BIS Total  G1: 55.60 (23.41)  G2: 46.70 (28.22)  Diff between groups (p=0.524)  Diff between groups in change over time (p=0.462)  BIS Attention  G1: 17.18 (3.59)  G2: 16.20 (4.82)  Diff between groups (p=0.649)  Diff between groups in change over time (p=0.440)  BIS Motor  G1: 21.41 (5.02)  G2: 20.86 (6.85)  Diff between groups (p=0.521)  Diff between groups in change over time (p=0.849)  BIS Nonplanning  G1: 24.59 (4.97)  G2: 21.31 (6.82)  Diff between groups (p=0.642)  Diff between groups in change over time (p=0.229) |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 200869 | Hamilton Depression Rating Scale (HAM-D)  Clinical Global Impression (CGI)  -severity  -improvement | HAM-D, M (SD)  G1: 4.6 (3.75)  G2: 5.7 (4.5)  p=NS  CGI-severity, M (SD)  G1: 4.8 (0.7)  G2: 4.7 (0.7)  p=NS | HAM-D, M (SD)  G1: 2.4 (2.9)  G2: 4.8 (5.1)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): 1.3 (-1.0, -3.5)  chi-square: 1.21  p=0.262  Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): 1.8 (-0.3, -3.9)  t=1.25  p=0.097  CGI-severity, M (SD)  G1: 2.3 (1.3)  G2: 3.2 (1.4)  Time-trend analysis  Estimate between-group difference in 12-week change (95% CI): 0.9 (0.1, -1.8)  chi-square: 4.56  p=0.029  Endpoint analysis  Estimate between-group difference in change from BL to final visit (95% CI): 1.0 (0.1, -1.9)  t=2.56  p=0.026  CGI-improvement scale:  "The mean final CGI-Improvement Scale at endpoint was rated much or very much improved in 17 (85%) of G1 as compared with 9 (39.1%) of G2 (p=0.029)." |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Guerdjikova, 201270 | Clinical Global Impression Severity for depressive disorders (CGI-S-DD)  Clinical Global Impression Improvement for depressive disorders (CGI-I-DD)  Inventory of Depressive Symptoms (IDC)  Hamilton Anxiety Scale (HAM-A) | CGI-S-DD  G1: 4.3 (0.7)  G2: 4.2 (0.7)  p = NR  IDS-C  G1: 35.6 (7.9)  G2: 35.4 (5.4)  p = NR  HAM-A  G1: 16.9 (9.1)  G2: 16.2 (5.7)  p = NR | CGI-S-DD  G1: 2.3 (1.3)  G2: 2.9 (1.0)  Longitudinal Analysis  d = 0.82  p = 0.01  Endpoint Analysis  d = 0.68  p = 0.03  CGI-I-DD  G1: 1.7 (1.1)  G2: 2.4 (1.4)  Endpoint Analysis  d = 0.34  p = 0.30  IDS-C  G1: 19.1 (11.5)  G2: 21.6 (12.7)  Longitudinal Analysis  d = 0.18  p = 0.58  Endpoint Analysis  d = 0.33  p = 0.32  50% or greater reduction IDS-C (response)  G1: 11  G2: 8  p = 0.19  IDS-C < 12 at endpoint (remission)  G1: 5  G2: 4  p = 0.71  HAM-A  G1: 9.6 (9.0)  G2: 7.2 (6.5)  Endpoint Analysis  d = 0.17  p = 0.60 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Hudson, 199871 | Hamilton depression scale score (HRDS) | HDRS, M (SD)  G1: 4.4 (3.6)  G2: 4.1 (3.7)  p=NR, NS | HDRS  Treatment-by-time interaction:  -0.401 (SE 0.359)  p=0.27 |
| Leombruni, 200872 | Beck Depression Inventory (BDI)  Clinical Global Impression (CGI) | BDI  G1: 11.1 (4.5)  G2: 13.3 (7.0)  CGI  G1: 4.0 (0.7)  G2: 3.8 (0.6) | BDI  T8  G1:8.7 (4.1)  G2: 8.6 (5.2)  T12  G1: 7.1 (4.1)  G2: 9.5 (5.9)  T24  G1: 8.4 (6.2)  G2: 9.9 (5.9)  time effect p<0.001  time x group effect p<0.640  CGI  T8  G1: 3.4 (0.8)  G2: 3.1 (0.8)  T12  G1: 2.9 (1.0)  G2: 3.0 (1.0)  T24  G1: 3.1 (0.9)  G2: 2.8 (0.9)  Time effect p<0.001  Time x group effect p<0.393 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200773 | Hamilton depression scale (HDRS)  Clinical Global Impression (CGI) severity | HDRS, mean (SD):  G1: 2.0 (2.4)  G2: 3.3 (3.6)  CGI severity, mean (SD):  G1: 4.2 (0.4)  G2: 4.4 (0.6) | HDRS:  Longitudinal Analysis  Estimate (mean change btwn g1 - g2): 0.58  95% CI: -1.33 to 2.49  X^2: 0.36  p: 0.551  Endpoint Analysis  Estimate (mean change btwn g1-g)2: -0.15  95% CI: -2.13 to 1.83  t: 0.15  p: 0.879  CGI severity  Longitudinal Analysis  Estimate (mean change btwn g1 - g2): -1.12  95% CI: -2.01 to -0.22  X^2: 6.03  p: 0.015  Endpoint Analysis  Estimate (mean change btwn g1-g)2: -1.20  95% CI: -1.90 to -0.50  t: 3.48  p: 0.013 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200674 | Hamilton Rating Scale for Depression (HAM-D)  Clinical Global Impression Severity (CGI-S) | HAM-D, mean (SD):  G1: 4.4 (SD 4.4)  G2: 4.9 (SD 5.5)  p=NR, NS  CGI-S, mean (SD):  G1: 4.7 (0.5)  G2: 4.5 (0.7)  p=NR, NS | HAM-D  Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -0.18 (95% CI -2.79 to 2.42)  p=0.892  Endpoint analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): 2.13 (95% CI -0.78 to 5.04)  p=0.147  CGI-S  Longitudinal analysis  G1: NR  G2: NR  Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo: -1.43 (95% CI -2.12 to -0.75)  p<0.001  Endpoint analysis  G1: NR  G2: NR |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200674  (continued) |  |  | Mean estimate (week 16 minus BL) for zonisamide minus mean (week 16 minus BL) for placebo (table also says that the "estimate is the test statistic, which is the mean difference in change scores (endpoint minus BL) between the zonisamide and placebo groups): -0.79 (95% CI -1.57 to 0.00)  p=0.049 |
| McElroy, 200375 | Hamilton Rating Scale for Depression (HAM-D)  Clinical Global Impression Severity (CGI-S) | HAM-D score, mean (SD)  G1: 3.1 (3.2)  G2: 2.7 (3.7)  p=NR, NS  CGI-S score, mean (SD)  G1: 4.5 (0.7)  G2: 5.0 (0.7)  p = 0.033 | HAM-D score, mean (SD)  G1: 1.4 (2.3)  G2: 1.9 (3.1)  Time Trend Analysis:  Mean difference between groups in rate of change: -1.05 (SE 0.54)  p=0.053  Endpoint Analysis:  Mean difference between groups in change from baseline to 6wk: -2.04 (SE 0.97)  p = 0.10  CGI-S, mean (SD)  G1: 2.4 (1.4)  G2: 3.6 (1.7)  Time Trend Analysis:  Mean difference between groups in rate of change: -0.475 (SE 0.217)  p = 0.28  Endpoint Analysis:  Mean difference between groups in change from BL to 6wk: -0.545 (SE 0.513)  p = 0.29 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200376 | Clinical Global Impression Severity Scale (CGI-S)  Hamilton Depression Rating Scale (HDRS) | CGI Severity Scale, mean (SD)  G1: 4.7 (0.9)  G2: 4.9 (0.8)  p = NS  HDRS, mean (SD)  G1: 5.9 (5.1)  G2: 5.8 (4.8)  p = NS | CGI Severity Scale, mean (SD)  G1: NR  G2: NR  Diff between groups, p = 0.01  Diff between groups in rate of change, p = 0.02  HDRS, mean (SD)  G1: NR  G2: NR  Diff between groups, p = NR  Diff between groups in rate of change, p = 0.28 |
| McElroy, 200077 | Hamilton depression rating scale (HDRS)  Clinical Global Impression (CGI)  - severity (CGI-S)  - improvement (CGI-I) | HDRS, mean (SD):  G1: 6.4 (3.9)  G2: 7.5 (8.4) | HDRS:  Diff in change between G1 & G2, mean: 1.33  SE: 1.00  p = 0.19  CGI-S:  Diff in change between G1 & G2, mean: -1.007  SE: 0.183  p < 0.001  G1 better than G2  CGI-I:  Diff in change between G1 & G2, mean: 0.929  SE: 0.929  p <0.001  G1 better than G2 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201178 | MADRS: Montgomery Asberg depression rating scale  CGI-S: Clinical global impression-severity scale  CGI-I: Clinical global impression-improvement scale | MADRS, mean (SD):  G1: 1.8 (2.0)  G2: 1.2 (1.4)  p = 0.30  CGI-S, mean (SD):  G1: 4.9 (0.8)  G2: 4.8 (0.9)  p = 0.71  CGI-I, mean (SD):  G1: 0.40 (1.23)  G2: 1.0 (1.78)  p = 0.22 | Endpoint Analysis:  CGI-S, mean (SD):  G1: 2.7 (1.7)  G2: 3.5 (1.4)  p = 0.09  CGI-I, mean (SD):  G1: 2.1 (1.1)  G2: 2.6 (1.1)  p = 0.96  MADRS, mean (SD):  G1: 1.4 (2.5)  G2: 1.8 (1.9)  p = 0.15 |
| McElroy, 200779 | Barrett Impulsiveness Scale (BIS-11)  Hamilton Anxiety Scale (HAM-A)  Montgomery Asberg depression rating scale (MDRS)  Clinical global impression-severity scale (CGI-S) | BIS-11, mean (SD)  Overall  G1: 64.2 (11.5)  G2: 65.7 (11.2)  Motor Impulsiveness, mean (SD)  G1: 22.8 (4.7)  G2: 23.1 (4.3)  Nonplanning Impulsiveness, mean (SD)  G1: 25.4 (5.3)  G2: 25.8 (5)  Attentional Impulsiveness, mean (SD)  G1: 16.0 (4.2)  G2: 16.8 (4.5)  HAM-A, mean (SD)  G1: 5.1 (4.8)  G2: 5.5 (5.1)  CGI-S, mean (SD)  G1: 4.8 (0.9)  G2: 4.8 (0.9) | BIS-11, mean (SD) change from baseline  Overall  G1: -3.9 (9.0)  G2: -1.4 (7.9)  Endpoint Analysis: p < 0.001  Longitudinal Analysis, rate of change: p = 0.003  Motor Impulsiveness, mean (SD) change from baseline  G1: -1.8 (3.8)  G2: -0.9 (3.7)  Endpoint Analysis: p = 0.004  Longitudinal Analysis, rate of change: p = 0.006  Nonplanning Impulsiveness, mean (SD) change from baseline  G1: -1.6 (4.5)  G2: 0.01 (3.7)  Endpoint Analysis: p < 0.001  Longitudinal Analysis, rate of change: p < 0.001 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 200779  (continued) |  |  | Attentional Impulsiveness, mean (SD) change from baseline  G1: -0.6 (3.6)  G2: -0.5 (3.1)  Endpoint Analysis: p = 0.230  Longitudinal Analysis, rate of change: p = 0.835  HAM-A, mean (SD) change from baseline  G1: -0.7 (4.9)  G2: -1.3 (4.5)  Endpoint Analysis, p = 0.493  Longitudinal Analysis, rate of change: p = 0.143  CGI-I, mean (SD) change from baseline  G1: -2.2 (1.6)  G2: -1.1 (1.4)  Endpoint Analysis, p <0.001  Longitudinal Analysis, rate of change: p < 0.001 |
| McElroy, 201380 | Beck Depression Inventory (BDI)  Clinical Global Impressions - Severity (CGI-S) | BDI, mean (SD)  G1: 3.7 (SD 2.8)  G2: 4.7 (SD 4.1)  p=0.29  CGI-Severity, mean (SD)  G1: 4.2 (SD 0.8)  G2: 4.4 (SD 0.7)  p=0.41 | BDI, mean change (SD) from baseline to endpoint  G1: -0.7 (SD 3.5)  G2: -2.4 (SD 4.1)  p=0.09  CGI-Severity, mean change (SD) from baseline to endpoint:  G1: -1.6 (SD 1.6)  G2: -2.1 (SD 1.3)  p=0.19 |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201581 | YBOCS-BE  Barratt Impulsiveness Scale (BIS-11)  SF-12 Aggregate Physical Health Component Summary Score  SF-12 Aggregate mental health component summary score  MADRS score  HAM-A score | YBOCS-BE score  G1: 20.7 (SD 4.87)  G2: 19.5 (SD 5.19)  G3: 19.8 (SD 5.48)  G4: 20.9 (SD 4.61)  BIS-11  G1: 61.8 (SD 10.70)  G2: 61.0 (SD 9.84)  G3: 61.4 (SD 12.69)  G4: 63.1 (SD 13.22)  MADRS score  G1: 2.9 (SD 3.02)  G2: 3.6 (SD 3.29)  G3: 3.7 (SD 3.94)  G4: 3.4 (SD 3.39)  HAM-A score  G1: 2.3 (SD 2.32)  G2: 2.3 (SD 2.60)  G3: 2.5 (SD 3.22)  G4: 2.5 (SD 3.01) | 11wk YBOCS-BE, LS change, mean (SE)  G1: -15.0 (SE 0.84)  G2: -15.3 (SE 0.83)  G3: -17.0 (SE 0.83)  G4: -12.0 (SE 0.87)  11wk YBOCS-BE, Difference from placebo, mean (SE)  G1: -2.97 (SE 1.203)  G2: -3.25 (SE 1.204)  G3: -4.93 (SE 1.202)  G4: N/A  11wk YBOCS-BE: Significant difference compared with placebo  G1 p=0.01  G2 p=0.008  G3 p<0.001  G4 N/A  11wk BIS-11, LS change, mean (SE)  G1: -5.8 (SE 1.05)  G2: -5.2 (SE 1.05)  G3: -6.9 (SE 1.05)  G4: -3.1 (SE 1.09)  11wk BIS-11, Difference from placebo, mean (SE)  G1: -2.7 (SE 1.52)  G2: -2.1 (SE 1.51)  G3: -3.7 (SE 1.51)  G4: N/A  11wk BIS-11: Significant difference compared with placebo  G1 p=0.08  G2 p=0.17  G3 p=0.02  G4 N/A |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| McElroy, 201581  (continued) |  |  | 11wk MADRS, LS change, mean (SE)  G1: -1.9 (SE 0.34)  G2: -1.3 (SE 0.33)  G3: -1.6 (SE 0.33)  G4: -1.7 (SE 0.35)  11wk MADRS, Difference from placebo, mean (SE)  G1: -0.15 (SE 0.484)  G2: 0.49 (SE 0.480)  G3: 0.14 (SE 0.480)  G4: N/A  11wk MADRS, Significant difference compared with placebo  G1 p=0.75  G2 p=0.31  G3 p=0.77  G4 N/A  11wk HAM-A, LS change, mean (SE)  G1: -0.9 (SE 0.29)  G2: -1.1 (SE 0.29)  G3: -0.6 (SE 0.29)  G4: -1.5 (SE 0.30)  11wk HAM-A, Difference from placebo, mean (SE)  G1: -0.9 (SE 0.29)  G2: -1.1 (SE 0.29)  G3: -0.6 (SE 0.29)  G4: -1.5 (SE 0.30)  11wk HAM-A, Significant difference compared with placebo  G1 p=0.20  G2 p=0.33  G3 p=0.05  G4 N/A |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| Pearlstein, 200382 | Beck Depression Inventory (BDI)  Hamilton Depression Scale (HAM-D  Hopkins Symptom Checklist (SCL-90)  Clinical Global Impression Scale (CGI) | BDI (M, SD):  G1: 0.44 (0.22)  G2: 0.68 (0.57)  (P = NS)  HAM-D (M,SD):  G1: 10.78 (9.22)  G2: 14.27 (12.40)  (P = NS)  SCL-90 (M,SD):  G1: 0.62 (0.33)  G2: 0.85 (0.55)  (P = NS)  CGI-Severity:  G1: NR  G2: NR | BDI (M,SD):  G1: 0.32 (0.30)  G2: 0.37 (0.26)  Diff between groups (P = NR)  Change over time for both groups: (P < 0.01)  Diff between groups in change over time (P = NS)  HAM-D (M,SD):  G1: 9.38 (9.71)  G2: 7.38 (6.16)  Diff between groups (P = NR)  Change over time for both groups: (P = NS)  Diff between groups in change over time (P = NS)  SCL-90 (M, SD):  G1: 0.30 (0.29)  G2: 0.40 (0.29)  Diff between groups (P = NR)  Change over time for both groups: (P < 0.001)  Diff between groups in change over time (P = NS)  CGI no improvment:  G1: 0  G2: 4)  p<0.07 |
| Shire, 201483,84 | Y-BOCS-BE total | G1: 21.8  G2: 21.5 | Change in Y-BOCS-BE total:  G1: -15.68  G2: -8.28  Diff: -7.4 (-8.9 to -5.9)  (p < 0.001) |
| Shire, 201484,85 | Y-BOCS-BE total | G1: 21.1  G2: 21.5 | Change in Y-BOCS-BE total:  G1: -15.36  G2: -7.42  Diff: -7.9 (-9.5 to -6.4)  (p < 0.001) |

Evidence Table 61. Binge eating disorder drug treatment – part 7 (continued)

|  |  |  |  |
| --- | --- | --- | --- |
| First Author's Last Name  Year | Definition of Psychopathology (BDI; STAI; BAI; RSE; BSQ) | Psychopathology Baseline | Psychopathology Outcomes |
| White, 201386 | Beck Depression Inventory (BDI)  Food Craving Inventory (FCI) | Beck Depression Inventory (BDI)  G1: 13.4 (SD 9.8)  G2: 10.8 (SD 6.1)  Food Craving Inventory (FCI)  G1: 2.6 (SD 0.6)  G2: 2.4 (SD 0.7) | 8wk Beck Depression Inventory (BDI)  G1: 8.0 (SD 8.3)  G2: 8.7 (SD 7.2)  Mixed effects model medication effect  F=0.04, p=0.84  8wk Food Craving Inventory (FCI)  G1: 2.0 (SD 0.6)  G2: 2.0 (SD 0.6)  Mixed effects model medication effect  F=0.10, p=0.76 |